RGBP (Regen BioPharma) Cyclically Adjusted PS Ratio: (As of Jul. 04, 2026)


What is Regen BioPharma Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Regen BioPharma  (OTCPK:RGBP) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Regen BioPharma Cyclically Adjusted PS Ratio Related Terms


Regen BioPharma Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for Regen BioPharma's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Regen BioPharma Cyclically Adjusted PS Ratio Chart

Regen BioPharma Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 1.23 0.16 0.04

Regen BioPharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.08 0.08 0.04 0.02 0.00

RGBP vs SIGY, ENDV, CNBX: Cyclically Adjusted PS Ratio Comparison

For the Biotechnology subindustry, Regen BioPharma's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Regen BioPharma Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Regen BioPharma's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Regen BioPharma's Cyclically Adjusted PS Ratio falls into.



Regen BioPharma Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Regen BioPharma's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 is calculated as:

For example, Regen BioPharma's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0/330.2130*330.2130
=0.000

Current CPI (Mar. 2026) = 330.2130.

Regen BioPharma Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 0.000 241.018 0.000
201609 0.543 241.428 0.743
201612 0.000 241.432 0.000
201703 0.000 243.801 0.000
201706 0.598 244.955 0.806
201709 0.000 246.819 0.000
201712 0.000 246.524 0.000
201803 0.000 249.554 0.000
201806 0.488 251.989 0.639
201809 0.000 252.439 0.000
201812 0.099 251.233 0.130
201903 0.069 254.202 0.090
201906 0.237 256.143 0.306
201909 0.035 256.759 0.045
201912 0.024 256.974 0.031
202003 0.013 258.115 0.017
202006 0.013 257.797 0.017
202009 0.013 260.280 0.016
202012 0.011 260.474 0.014
202103 0.008 264.877 0.010
202106 0.012 271.696 0.015
202109 0.011 274.310 0.013
202112 0.010 278.802 0.012
202203 0.010 287.504 0.011
202206 0.009 296.311 0.010
202209 0.010 296.808 0.011
202212 0.009 296.797 0.010
202303 0.018 301.836 0.020
202306 0.009 305.109 0.010
202309 0.007 307.789 0.008
202312 0.008 306.746 0.009
202403 0.007 312.332 0.007
202406 0.007 314.175 0.007
202409 0.007 315.301 0.007
202412 0.007 315.605 0.007
202503 0.003 319.799 0.003
202506 0.002 322.561 0.002
202509 0.002 324.800 0.002
202512 0.001 324.054 0.001
202603 0.000 330.213 0.000

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Regen BioPharma Business Description

Other Exchanges RGBPP.PFD:USA
Address 8697 La Mesa Boulevard, Suite C, La Mesa, CA, USA, 91942
Regen BioPharma Inc is a USA-based biotechnology company. It focuses on the development of regenerative medical applications in the stem cell space. The company's principal products and services include HemaXellarate I, HemaXellerate II, dCell Vax, NR2F6, Tcellvax, identification of Small Molecules, and others. HemaXellarate I and HemaXellerate II are cellular therapies designed to heal damaged bone marrow. dCell Vax is a therapy whereby dendritic cells of the cancer patient are harvested from the body. Tcellvax is an autologous cellular product comprised of NR2F6 gene-silenced peripheral blood mononuclear cells.